Volume 30, Issue 2 pp. 194-200
Original Article

Ventricular Assist Devices and Increased Blood Product Utilization for Cardiac Transplantation

Matthew L. Stone M.D.

Matthew L. Stone M.D.

Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
Damien J. LaPar M.D., M.Sc.

Damien J. LaPar M.D., M.Sc.

Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
Ehsan Benrashid M.D.

Ehsan Benrashid M.D.

University of Virginia School of Medicine, Charlottesville, Virginia

Search for more papers by this author
David C. Scalzo M.D.

David C. Scalzo M.D.

Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
Gorav Ailawadi M.D.

Gorav Ailawadi M.D.

Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
Irving L. Kron M.D.

Irving L. Kron M.D.

Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
James D. Bergin M.D.

James D. Bergin M.D.

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
Randal S. Blank M.D., Ph.D.

Randal S. Blank M.D., Ph.D.

Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia

Search for more papers by this author
John A. Kern M.D.

Corresponding Author

John A. Kern M.D.

Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia

Address for correspondence: John A. Kern, M.D., University of Virginia Health System, Division of Thoracic and Cardiovascular Surgery, P.O. Box 800679, Charlottesville, VA 22908-0679. Fax: +434 243–5781; e-mail: [email protected]

Search for more papers by this author
First published: 21 December 2014
Citations: 13
Conflict of interest: The authors acknowledge no conflict of interest in the submission.
Presentation disclosure: Pilot study findings presented at the American Heart Association, Orlando, Florida, November 12-13, 2012.

ABSTRACT

Background and Aim of Study

The purpose of this study was to examine whether blood product utilization, one-year cell-mediated rejection rates, and mid-term survival significantly differ for ventricular assist device (VAD patients compared to non-VAD (NVAD) patients following cardiac transplantation.

Methods

From July 2004 to August 2011, 79 patients underwent cardiac transplantation at a single institution. Following exclusion of patients bridged to transplantation with VADs other than the HeartMate II® LVAD (n = 10), patients were stratified by VAD presence at transplantation: VAD patients (n = 35, age: 54.0 [48.0–59.0] years) vs. NVAD patients (n = 34, age: 52.5 [42.8–59.3] years). The primary outcomes of interest were blood product transfusion requirements, one-year cell-mediated rejection rates, and mid-term survival post-transplantation.

Results

Preoperative patient characteristics were similar for VAD and NVAD patients. NVAD patients presented with higher median preoperative creatinine levels compared to VAD patients (1.3 [1.1–1.6] vs. 1.1 [0.9–1.4], p = 0.004). VAD patients accrued higher intraoperative transfusion of all blood products (all p ≤ 0.001) compared to NVAD patients. The incidence of clinically significant cell-mediated rejection within the first posttransplant year was higher in VAD compared to NVAD patients (66.7% vs. 33.3%, p = 0.02). During a median follow-up period of 3.2 (2.0, 6.3) years, VAD patients demonstrated an increased postoperative mortality that did not reach statistical significance (20.0% vs. 8.8%, p = 0.20).

Conclusions

During the initial era as a bridge to transplantation, the HeartMate II® LVAD significantly increased blood product utilization and one-year cell-mediated rejection rates for cardiac transplantation. Further study is warranted to optimize anticoagulation strategies and to define causal relationships between these factors for the current era of cardiac transplantation. doi: 10.1111/jocs.12474 (J Card Surg 2015;30:194–200)

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.